
BusinessWire
Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement
January 26th, 2021
BusinessWire
Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement
January 26th, 2021
bioworld
Fuzionaire, Canadian researchers shine light on neurodegenerative diseases
David Godkin – February 28th, 2020
parkinsonsnewstoday
Collaboration Formed to Develop New Radiochemicals for Diagnosing, Treating Brain Diseases
Patricia Inacio, PHD – February 5th, 2020
dotmed
Three-way collaboration to introduce radiopharmaceuticals for brain diseases
John R. Fischer – February 3rd, 2020
Dr. Toutov holds a PhD in organic chemistry from Caltech in the laboratory of Nobel Laureate Robert H. Grubbs, where he held Dow-Resnick, NSERC, and Bristol-Myers Squibb fellowships. Dr. Toutov collectively has over 40 scholarly articles and patent grants and applications to his name spanning the fields of chemical synthesis, clean energy, and drug discovery. Among them is the discovery of a new form of catalysis, which was first published in Nature and was later presented to general audiences in the documentary film Element 19. He is the recipient of the 2016 Demetriades Caltech Thesis Prize, the 2015 Alfred Bader Award for Student Innovation (Sigma-Aldrich Corporation), the 2014 Dow Chemical Sustainability Challenge Grand Prize, and the 2014 Milliken & Co. “Deep Science” award, among others. Dr. Toutov also serves as senior technical advisor to the Gates Foundation-backed Medicines for All Institute, improving access to affordable, high-quality medicines.